COMP <GO>
ETON vs OCUL // EV/EBITDA & P/E VALUATION
Eton Pharmaceuticals Inc. (NASDAQ) VS. Ocular Therapeutix Inc. (NASDAQ) • 15-METRIC TALLY: ETON 8
— OCUL 2
■ METRIC PARITY
LAST: $50.81 (-2.63%) • MKT CAP: $1.49B
valuation
—
LAST: $6.73 (-3.44%) • MKT CAP: $1.53B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. OCUL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ETON | OCUL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 87.30% | -33.80 | OCUL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.90% | -35.00% | +34.10 | ETON | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.66% | -13.51% | +14.17 | ETON | /fcf-yield <GO> |
| Operating Margin | -1.10% | -60.00% | +58.90 | ETON | /operating-margins <GO> |
| Net Profit Margin | -5.80% | -60.00% | +54.20 | ETON | /net-margins <GO> |
| Revenue Growth (YoY) | 104.90% | -18.50% | +123.40 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.37 | 4.31 | +9.06 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | ETON | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 43.3 | +4.60 | ETON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.49B | $1.53B | -$39.3M | OCUL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ETON REV | OCUL REV | ETON GROSS % | OCUL GROSS % | ETON FCF | OCUL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.0M | $52.0M | 53.5% | 87.3% | $10.2M | -$216.9M |
| FY 2024 | $39.0M | $63.7M | 60.0% | 91.2% | $943.0K | -$136.0M |
| FY 2023 | $31.6M | $58.4M | — | — | $6.8M | -$70.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
OCUL // BETA —